World’s First Hormogenetics™ Platform to Transform Women’s Health and Longevity

(3 votes, average: 5.00 out of 5)

Loading...

By Yulia Mintchin, Founder and CEO of Willbe

Perimenopause, affecting over 1 billion women globally, remains one of the most underserved areas of healthcare. Standard approaches often rely on years of trial and error, leaving women and their doctors frustrated, unsupported, and at risk of preventable age-related conditions.

Image: AI generated

Perimenopause is not just declining hormones — it’s an epigenetic reprogramming event. The body says: the way I used to run no longer works. Whether a woman thrives or struggles is written in her genes. As hormones decline, gene expression shifts — driving how she ages, repairs, and restores. That’s why women on the same HRT dose can have completely different outcomes. By decoding each woman’s genetic blueprint, we can predict her hormonal journey and deliver targeted solutions from day one. This is the moment women move beyond trial-and-error healthcare into precision longevity medicine.

Proprietary sciences — Hormogenomics™ and Hormogenetics™ — deliver a precision solution by predicting how a woman’s body will metabolize and respond to declining hormones, long before symptoms take hold.

Through its Hormonal Archetypes™ methodology, Willbe classifies women into clear hormonal archetypes rooted in genetics that guide treatment pathways with accuracy and confidence. Unlike traditional one-size-fits-all care, this personalized approach enables faster relief, longer adherence to BHRT, and ultimately supports healthier, longer lives for women.

Willbe, the pioneering female health and longevity platform founded by Forbes 30 Under 30 entrepreneur and biomedical scientist Yulia Mintchin, has announced the launch of its flagship genetic innovation, FemGene®, the world’s first test built to decode how women uniquely experience perimenopause and respond to bioidentical hormone therapy (BHRT).

Willbe bridges functional and traditional medicine, offering women access to advanced testing, personalised longevity protocols, and expert support. The launch of FemGene^® positions Willbe as the category leader in female hormonal health and longevity, bridging hormones, skin health and preventative medicine.

About Willbe

Willbe is a UK-based female health and longevity company, redefining perimenopause as the front door to female longevity. Combining genetics, hormone testing, and bioidentical HRT, Willbe’s Hormogenetics™ platform offers predictive, personalized healthcare that empowers women to extend their health-span. Willbe’s mission is to transform female health from reactive to preventative and to save billions of women the cost of unnecessary and absolutely preventable suffering.

      Yulia Mintchin is Forbes 30U30 tech entrepreneur, biomedical scientist and founder of Willbe – a genetic-based hormonal care platform for women in perimenopause. Willbe gives women the clarity they deserve – understanding their symptoms, finding solutions that truly work and protecting their long-term health. Yulia speaks globally on female health and longevity, inspiring women to see ageing not as decline, but as a possibility.

The views and opinions expressed in this blog post or content are those of the authors or the interviewees and do not necessarily reflect the official policy or position of any other agency, organization, employer, or company.